Home / Latest Reports / Intravenous Iv Iron Drugs Market

Intravenous (IV) Iron Drugs Market By Product Type and Therapeutic Application - Global Industry Analysis And Forecast To 2027

Published On : November 2018 Pages : 180 Category: Pharma & Healthcare Report Code : HC111693

Request Sample Inquiry Before Buying Request for Customization Check Discount

Intravenous (IV) Iron Drugs Market By Product Type (Ferric Gluconate, Iron Sucrose, Ferric Carboxyl Maltose and Low Molecular Weight Iron Dextran) and Therapeutic Application (Gastroenterology, Chronic Heart Failures, Nephrology, Surgeries, Oncology and Gynecology) - Global Industry Analysis And Forecast To 2027

Industry Outlook

The iron infusion is the process in which the iron is conveyed to the body intravenously, which means into the vein by utilizing needle. This technique for conveying the medicine or the supplementation is otherwise known as the intravenous (IV) infusion. These infusions are generally endorsed by the specialists to treat the anemia caused by iron deficiency. This anemia is commonly treated with the dietary alterations and the iron supplements which are taken in form of pill. At times, however, specialists may prescribe the iron infusions. Therefore, the Intravenous (IV) Iron Drugs Market is anticipated to expand and has tremendous scope during the forecast period. The global Intravenous (IV) Iron Drugs Market anticipated to flourish in the future by growing at a significantly higher CAGR.

Market Segmentation

Based on Type the market is segmented into Ferric Gluconate, Iron Sucrose, Ferric Carboxyl Maltose and Low Molecular Weight Iron Dextran. The Ferric Gluconate section is leading the market while the Ferric Carboxyl Maltose section is expected significant growth owing to rising applications in the processes of drug discovery, less cost, higher performance.

Based on Application the market is segmented into Gastroenterology, Chronic Heart Failures, Nephrology, Surgeries, Oncology and Gynecology. The Nephrology section is leading the market due to rising utilization of these drugs & various related therapies. However the Chronic Heart Failures section is showing profitable growth during the foreseen period due to increasing number of cases related to the heart disorders.

Regional Insights

The North American region is leading the global Intravenous (IV) Iron Drugs Market due to factor like; rising number of applications of these drugs in the research of cancer, rising adoption & demand for the cost-effective & compact drugs, etc.

Intravenous (IV) Iron Drugs Market, By Region

    • North America
  • U.S.
  • Canada
  • Mexico
    • Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
    • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Southeast Asia
  • Rest of Asia-Pacific
    • South America
  • Brazil
  • Argentina
  • Columbia
  • Rest of South America
    • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of MEA

Competitive Analysis

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.

  • AMAG Pharmaceuticals Inc.
  • Rockwell Medical Technologies Inc.
  • Pharmacosmos A/S
  • Sanofi
  • American Regent Inc.
  • Actavis Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Luitpold Pharmaceuticals Inc.
  • Vifor Pharma Ltd.
  • Galenica Ltd.

Some of the key questions answered by the report are:          

  • What was the market size in 2017 and forecast from 2017 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

o   Intravenous (IV) Iron Drugs Market, By Product Type, Estimates and Forecast, 2017-2027 ($Million)

o   Ferric Gluconate

o   Iron Sucrose

o   Ferric Carboxyl Maltose

o   Low Molecular Weight Iron Dextran

o   Intravenous (IV) Iron Drugs Market, By Therapeutic Application, Estimates and Forecast, 2017-2027 ($Million)

o   Gastroenterology

o   Chronic Heart Failures

o   Nephrology

o   Surgeries

o   Oncology

o   Gynecology

o   Intravenous (IV) Iron Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

o   North America

§  North America Intravenous (IV) Iron Drugs Market , By Country

o   U.S. Intravenous (IV) Iron Drugs Market

o   Canada Intravenous (IV) Iron Drugs Market

o   Mexico Intravenous (IV) Iron Drugs Market

o   Europe

§  Europe Intravenous (IV) Iron Drugs Market , By Country

o   Germany Intravenous (IV) Iron Drugs Market

o   UK Intravenous (IV) Iron Drugs Market

o   France Intravenous (IV) Iron Drugs Market

o   Russia Intravenous (IV) Iron Drugs Market

o   Italy Intravenous (IV) Iron Drugs Market

o   Rest of Europe Intravenous (IV) Iron Drugs Market

o   Asia-Pacific

§  Asia-Pacific Intravenous (IV) Iron Drugs Market , By Country

o   China Intravenous (IV) Iron Drugs Market

o   Japan Intravenous (IV) Iron Drugs Market

o   South Korea  Intravenous (IV) Iron Drugs Market

o   India Intravenous (IV) Iron Drugs Market

o   Southeast Asia Intravenous (IV) Iron Drugs Market

o   Rest of Asia-Pacific Intravenous (IV) Iron Drugs Market

o   South America

§  South America Intravenous (IV) Iron Drugs Market , By Country

o   Brazil Intravenous (IV) Iron Drugs Market

o   Argentina Intravenous (IV) Iron Drugs Market

o   Columbia Intravenous (IV) Iron Drugs Market

o   Rest of South America Intravenous (IV) Iron Drugs Market

o   Middle East and Africa

§  Middle East and Africa Intravenous (IV) Iron Drugs Market , By Country

o   Saudi Arabia Intravenous (IV) Iron Drugs Market

o   UAE Intravenous (IV) Iron Drugs Market

o   Egypt Intravenous (IV) Iron Drugs Market

o   Nigeria Intravenous (IV) Iron Drugs Market

o   South Africa Intravenous (IV) Iron Drugs Market

o   Rest of MEA Intravenous (IV) Iron Drugs Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

3.3.     SWOT Analysis

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Intravenous (IV) Iron Drugs  Market, By Product Type

5.1.     Introduction

5.2.     Global Intravenous (IV) Iron Drugs  Revenue and Market Share by Product Type (2017-2027)

5.2.1.  Global Intravenous (IV) Iron Drugs  Revenue and Revenue Share by Product Type (2017-2027)

5.3.     Ferric Gluconate

5.3.1.  Global Ferric Gluconate Revenue and Growth Rate (2017-2027)

5.4.     Iron Sucrose

5.4.1.  Global Iron Sucrose  Revenue and Growth Rate (2017-2027)

5.5.     Ferric Carboxyl Maltose

5.5.1.  Global Ferric Carboxyl Maltose  Revenue and Growth Rate (2017-2027)

5.6.     Low Molecular Weight Iron Dextran

5.6.1.  Global Low Molecular Weight Iron Dextran  Revenue and Growth Rate (2017-2027)

6.       Intravenous (IV) Iron Drugs  Market, By Therapeutic Application

6.1.     Introduction

6.2.     Global Intravenous (IV) Iron Drugs  Revenue and Market Share by Therapeutic Application (2017-2027)

6.2.1.  Global Intravenous (IV) Iron Drugs  Revenue and Revenue Share by Therapeutic Application (2017-2027)

6.3.     Gastroenterology

6.3.1.  Global Gastroenterology Revenue and Growth Rate (2017-2027)

6.4.     Chronic Heart Failures

6.4.1.  Global Chronic Heart Failures  Revenue and Growth Rate (2017-2027)

6.5.     Nephrology

6.5.1.  Global Nephrology  Revenue and Growth Rate (2017-2027)

6.6.     Surgeries

6.6.1.  Global Surgeries Revenue and Growth Rate (2017-2027)

6.7.     Oncology

6.7.1.  Global Oncology  Revenue and Growth Rate (2017-2027)

6.8.     Gynecology

6.8.1.  Global Gynecology  Revenue and Growth Rate (2017-2027)

7.       Intravenous (IV) Iron Drugs  Market, By Region

7.1.     Introduction

7.2.     Global Intravenous (IV) Iron Drugs  Revenue and Market Share by Regions

7.2.1.  Global Intravenous (IV) Iron Drugs  Revenue by Regions (2017-2027)

7.3.     North America Intravenous (IV) Iron Drugs  by Countries

7.3.1.  North America Intravenous (IV) Iron Drugs  Revenue and Growth Rate (2017-2027)

7.3.2.  North America Intravenous (IV) Iron Drugs  Revenue (Million USD) by Countries (2017-2027)

7.3.3.  United States

7.3.3.1.  United States Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.3.4.  Canada

7.3.4.1.  Canada Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.3.5.  Mexico

7.3.5.1.  Mexico Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.     Europe Intravenous (IV) Iron Drugs  by Countries

7.4.1.  Europe Intravenous (IV) Iron Drugs  Revenue and Growth Rate (2017-2027)

7.4.2.  Europe Intravenous (IV) Iron Drugs  Revenue (Million USD) by Countries (2017-2027)

7.4.3.  Germany

7.4.3.1.  Germany Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.4.  France

7.4.4.1.  France Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.5.  UK

7.4.5.1.  UK Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.6.  Russia

7.4.6.1.  Russia Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.7.  Italy

7.4.7.1.  Italy Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.8.  Rest of Europe

7.4.8.1.  Rest of Europe Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.     Asia-Pacific Intravenous (IV) Iron Drugs  by Countries

7.5.1.  Asia-Pacific Intravenous (IV) Iron Drugs  Revenue and Growth Rate (2017-2027)

7.5.2.  Asia-Pacific Intravenous (IV) Iron Drugs  Revenue (Million USD) by Countries (2017-2027)

7.5.3.  China

7.5.3.1.  China Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.4.  Japan

7.5.4.1.  Japan Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.5.  Korea

7.5.5.1.  Korea Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.6.  India

7.5.6.1.  India Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.7.  Southeast Asia

7.5.7.1.  Southeast Asia Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.8.  Rest of Asia-Pacific

7.5.8.1.  Rest of Asia-Pacific Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.     South America Intravenous (IV) Iron Drugs  by Countries

7.6.1.  South America Intravenous (IV) Iron Drugs  Revenue and Growth Rate (2017-2027)

7.6.2.  South America Intravenous (IV) Iron Drugs  Revenue (Million USD) by Countries (2017-2027)

7.6.3.  Brazil

7.6.3.1.  Brazil Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.4.  Argentina

7.6.4.1.  Argentina Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.5.  Columbia

7.6.5.1.  Columbia Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.6.  Rest of South America

7.6.6.1.  Rest of South America Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.     Middle East and Africa Intravenous (IV) Iron Drugs  by Countries

7.7.1.  Middle East and Africa Intravenous (IV) Iron Drugs  Revenue and Growth Rate (2017-2027)

7.7.2.  Middle East and Africa Intravenous (IV) Iron Drugs  Revenue (Million USD) by Countries (2017-2027)

7.7.3.  Saudi Arabia

7.7.3.1.  Saudi Arabia Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.4.  United Arab Emirates

7.7.4.1.  United Arab Emirates Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.5.  Egypt

7.7.5.1.  Egypt Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.6.  Nigeria

7.7.6.1.  Nigeria Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.7.  South Africa

7.7.7.1.  South Africa Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.8.  Turkey

7.7.8.1.  Turkey Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.9.  Rest of Middle East and Africa

7.7.9.1.  Rest of Middle East and Africa Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

8.       Company Profiles

8.1.     AMAG Pharmaceuticals Inc.

8.1.1.  Business Overview

8.1.2.   Service Portfolio

8.1.3.  Strategic Developments

8.1.4.   Revenue and Market Share

8.2.     Rockwell Medical Technologies Inc.

8.2.1.  Business Overview

8.2.2.   Service Portfolio

8.2.3.  Strategic Developments

8.2.4.   Revenue and Market Share

8.3.     Pharmacosmos A/S

8.3.1.  Business Overview

8.3.2.   Service Portfolio

8.3.3.  Strategic Developments

8.3.4.   Revenue and Market Share

8.4.     Sanofi

8.4.1.  Business Overview

8.4.2.   Service Portfolio

8.4.3.  Strategic Developments

8.4.4.   Revenue and Market Share

8.5.     American Regent Inc.

8.5.1.  Business Overview

8.5.2.   Service Portfolio

8.5.3.  Strategic Developments

8.5.4.   Revenue and Market Share

8.6.     Actavis Inc.

8.6.1.  Business Overview

8.6.2.   Service Portfolio

8.6.3.  Strategic Developments

8.6.4.   Revenue and Market Share

8.7.     Fresenius Medical Care AG & Co. KGaA

8.7.1.  Business Overview

8.7.2.   Service Portfolio

8.7.3.  Strategic Developments

8.7.4.   Revenue and Market Share

8.8.     Luitpold Pharmaceuticals Inc.

8.8.1.  Business Overview

8.8.2.   Service Portfolio

8.8.3.  Strategic Developments

8.8.4.   Revenue and Market Share

8.9.     Vifor Pharma Ltd.

8.9.1.  Business Overview

8.9.2.   Service Portfolio

8.9.3.  Strategic Developments

8.9.4.   Revenue and Market Share

8.10. Galenica Ltd.

8.10.1.      Business Overview

8.10.2.       Service Portfolio

8.10.3.      Strategic Developments

8.10.4.       Revenue and Market Share

9.       Global Intravenous (IV) Iron Drugs  Market Competition, by Manufacturer

9.1.     Global Intravenous (IV) Iron Drugs  Revenue and Market Share by Manufacturer (2017-2017)

9.2.     Global Intravenous (IV) Iron Drugs  Price By Region (2017-2017)

9.3.     Top 5 Intravenous (IV) Iron Drugs  Manufacturer Market Share

9.4.     Market Competition Trend

10.    Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.1. Global Intravenous (IV) Iron Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

10.2. Intravenous (IV) Iron Drugs  Market Forecast by Regions (2017-2027)

10.2.1.      North America Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.1.1. United States Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.1.2. Canada Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.1.3. Mexico Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.2.      Europe Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.2.1. Germany Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.2.2. France Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.2.3. UK Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.2.4. Russia Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.2.5. Italy Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.2.6. Rest of Europe Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.3.      Asia-Pacific Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.3.1. China Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.3.2. Japan Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.3.3. Korea Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.3.4. India Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.3.5. Southeast Asia Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.3.6. Rest of Asia-Pacific Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.4.      South America Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.4.1. Brazil Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.4.2. Argentina Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.4.3. Columbia Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.4.4. Rest of South America Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.5.      Middle East and Africa Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.5.1. Saudi Arabia Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.5.2. United Arab Emirates Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.5.3. Egypt Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.5.4. Nigeria Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.5.5. South Africa Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.5.6. Turkey Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.2.5.7. Rest of Middle East and Africa Intravenous (IV) Iron Drugs  Market Forecast (2017-2027)

10.3. Intravenous (IV) Iron Drugs  Market Forecast by Product Type (2017-2027)

10.3.1.      Intravenous (IV) Iron Drugs  Forecast by Product Type (2017-2027)

10.3.2.      Intravenous (IV) Iron Drugs  Market Share Forecast by Product Type (2017-2027)

10.4. Intravenous (IV) Iron Drugs  Market Forecast by Therapeutic Application (2017-2027)

10.4.1.      Intravenous (IV) Iron Drugs  Forecast by Therapeutic Application (2017-2027)

10.4.2.      Intravenous (IV) Iron Drugs  Market Share Forecast by Therapeutic Application (2017-2027)

List of Tables

List of Tables and Figures:

Figure United States Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Intravenous (IV) Iron Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Intravenous (IV) Iron Drugs Revenue and Revenue Share by Product Type (2017-2018)
Figure Global Ferric Gluconate Revenue and Growth Rate (2017-2018)
Figure Global Iron Sucrose Revenue and Growth Rate (2017-2018)
Figure Global Ferric Carboxyl Maltose Revenue and Growth Rate (2017-2018)
Figure Global Low Molecular Weight Iron Dextran Revenue and Growth Rate (2017-2018)
Table Global Intravenous (IV) Iron Drugs Revenue and Revenue Share by Therapeutic Application (2017-2018)
Figure Global Gastroenterology Revenue and Growth Rate (2017-2018)
Figure Global Chronic Heart Failures Revenue and Growth Rate (2017-2018)
Figure Global Nephrology Revenue and Growth Rate (2017-2018)
Figure Global Surgeries Revenue and Growth Rate (2017-2018)
Figure Global Oncology Revenue and Growth Rate (2017-2018)
Figure Global Gynecology Revenue and Growth Rate (2017-2018)
Table Global Intravenous (IV) Iron Drugs Revenue by Regions (2017-2018)
Figure North America Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure North America Intravenous (IV) Iron Drugs Revenue and Growth Rate (2017-2018)
Figure North America Intravenous (IV) Iron Drugs by Countries (2017-2018)
Figure North America Intravenous (IV) Iron Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure United States Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Canada Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Mexico Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Europe Intravenous (IV) Iron Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Intravenous (IV) Iron Drugs by Countries (2017-2018)
Figure Europe Intravenous (IV) Iron Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Germany Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure France Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure UK Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Russia Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Italy Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Rest of Europe Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Intravenous (IV) Iron Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Intravenous (IV) Iron Drugs by Countries (2017-2018)
Figure Asia-Pacific Intravenous (IV) Iron Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure China Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Japan Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Korea Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure India Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Southeast Asia Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure South America Intravenous (IV) Iron Drugs Revenue and Growth Rate (2017-2018)
Figure South America Intravenous (IV) Iron Drugs by Countries (2017-2018)
Figure South America Intravenous (IV) Iron Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Brazil Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Argentina Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Columbia Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Rest of South America Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Intravenous (IV) Iron Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Intravenous (IV) Iron Drugs by Countries (2017-2018)
Figure Middle East and Africa Intravenous (IV) Iron Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Egypt Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Nigeria Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure South Africa Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Turkey Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Intravenous (IV) Iron Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table AMAG Pharmaceuticals Inc. Intravenous (IV) Iron Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Rockwell Medical Technologies Inc. Intravenous (IV) Iron Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pharmacosmos A/S Intravenous (IV) Iron Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sanofi Intravenous (IV) Iron Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table American Regent Inc. Intravenous (IV) Iron Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Actavis Inc. Intravenous (IV) Iron Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Fresenius Medical Care AG & Co. KGaA Intravenous (IV) Iron Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Luitpold Pharmaceuticals Inc. Intravenous (IV) Iron Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Vifor Pharma Ltd. Intravenous (IV) Iron Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Galenica Ltd. Intravenous (IV) Iron Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Intravenous (IV) Iron Drugs Market Share by Manufacturer
Figure Global Intravenous (IV) Iron Drugs Revenue and Market Share by Manufacturer
Table Global Intravenous (IV) Iron Drugs Price by Region (2017-2017)
Figure Top 5 Intravenous (IV) Iron Drugs Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Intravenous (IV) Iron Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Intravenous (IV) Iron Drugs Market Forecast by Regions (2018-2025)
Figure North America Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure United States Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Canada Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Mexico Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Europe Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Germany Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure France Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure UK Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Russia Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Italy Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Rest of Europe Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure China Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Japan Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Korea Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure India Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Southeast Asia Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure South America Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Brazil Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Argentina Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Columbia Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Rest of South America Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Egypt Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Nigeria Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure South Africa Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Turkey Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Intravenous (IV) Iron Drugs Market Forecast (2018-2025)
Figure Global Intravenous (IV) Iron Drugs Forecast by Product Type (2018-2025)
Figure Global Intravenous (IV) Iron Drugs Market Share Forecast by Product Type (2018-2025)
Figure Global Intravenous (IV) Iron Drugs Forecast by Product Type (2018-2025)
Figure Global Intravenous (IV) Iron Drugs Forecast by Therapeutic Application (2018-2025)
Figure Global Intravenous (IV) Iron Drugs Market Share Forecast by Therapeutic Application (2018-2025)
Figure Global Intravenous (IV) Iron Drugs Forecast by Therapeutic Application (2018-2025)

Please Note: Data related to the Companies are subject to Availability.

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*